To hear about similar clinical trials, please enter your email below
Trial Title:
The Roles of Exosomal Circ-LRBA and 451/CRTC2 Signaling Axis in Colorectal Cancer
NCT ID:
NCT05579353
Condition:
Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
nothing
Description:
nothing
Arm group label:
cancer group
Arm group label:
control group
Summary:
Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Most of
the patients with colorectal cancer were diagnosed in poor stage. Although 40% to 50%
patients of colorectal cancer can be cured by surgery, but most patients have undergent
metastasis or recurrence, and eventually death. In recent years, molecular targeted
therapy has shown significant efficacy in specific patients. It was necessary to detect
the corresponding molecular targets of tumors before selecting appropriate targeted drugs
in clinic. The changing state of related gene molecules in colorectal cancer played a key
role in drug selection, there were few effective targets so far. At present, metastasis
and recurrence still be the most difficult problems in treatment. Therefore,
investigators should deeply study the occurrence and development of colorectal cancer at
the gene level and look for new biomarkers to predict the prognosis. Furthermore, the
study can clarify the exact molecular mechanism of colorectal cancer. These will be
important clinical significance for targeted therapy of colorectal cancer.
Criteria for eligibility:
Study pop:
1
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1.18-80 years old.
2.18.5 < BMI < 27.9.
3. The surgical methods are radical resection of rectal cancer, resection of right
colon cancer, resection of left colon cancer and radical resection of sigmoid colon
cancer.
Exclusion Criteria:
1. Those who refuse to collect samples.
2. Patients with severe dysfunction of coagulation, hepatorenal dysfunction or severe
cardiopulmonary diseases.
3. Patients who has a history of neoadjuvant radiotherapy or chemotherapy.
4. Combining with distant multiple metastases of tumor
Gender:
All
Minimum age:
18 Years
Maximum age:
80 Years
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
The First Affiliated Hospital of Shandong First Medical University
Address:
City:
Jinan
Zip:
250014
Country:
China
Status:
Recruiting
Contact:
Last name:
Jingbo Chen, doctor
Phone:
15053186972
Phone ext:
nothing
Email:
qychenjingbo@163.com
Start date:
January 1, 2023
Completion date:
December 31, 2026
Lead sponsor:
Agency:
Jingbo Chen
Agency class:
Other
Source:
Qianfoshan Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05579353
